Sikander Ailawadhi, M.D.
Senior Associate Consultant
Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Florida
Award received while at USC Norris Comprehensive Cancer Center

Sikander Ailawadhi, M.D. was awarded the 2013 NCI CCITLA as an Assistant Professor of Medicine at the Norris Cancer Center, University of Southern California (USC), Los Angeles CA. Subsequently, he has joined the Division of Hematology and Oncology at Mayo Clinic in Florida as a Senior Associate Consultant in order to pursue his career goal of clinical, translational and outcomes-based research in B-cell malignancies, especially plasma cell disorders. Prior to his move from USC, under the scope of CCITLA, Dr. Ailawadhi was involved with the following efforts:

1. Expansion and continuation of the function of the Quality Assurance and Monitoring Committee (QAMC) and Clinical Investigation Support Office (CISO): As the QAMC Chair, Dr. Ailawadhi was involved in an effort to expand the membership of the QAMC by recruiting more clinicians and allied staff from diverse backgrounds to the committee.
2. Development of disease-specific clinical trial pathways in hematologic malignancies: Dr. Ailawadhi developed four disease-specific clinical trial pathways for dysproteinemia, acute leukemias, chronic leukemias and lymphomas so that all the open clinical trials within the Division of Hematology would be prioritized and the clinicians/housestaff would know about the salient inclusion criteria as well as prioritization of disease-specific clinical trials at a glance. These were then delegated to respective faculty with interest in specific disease types to maintain in a prospective manner.
3. Monitoring and promoting racial/ethnic diversity in clinical trial participation at USC: Dr. Ailawadhi prepared a proposal to the IRB that was approved and was aimed at defining the ethnic mix of patients reported to the California Cancer Registry, patients seen at USC and those enrolled in clinical trials at USC to define the catchment population as well as the actual accrual population and their ethnic mix. This would be used to develop tools to increase clinical trial participation by ethnic minorities.
4. Expansion of the Cooperative Group clinical trial participation in hematologic malignancies at USC: Dr. Ailawadhi continues as the Study Chair of S1304 and co-Chair of S1211 Intergroup clinical trials and secured a randomized phase 2 clinical trial concept in Waldenstrom's macroglobulinemia through his involvement with SWOG. He is currently working on submitting the letter of intent to NCI/CTEP for their approval.

Jessica Altman, M.D.
Director of the Leukemia Program for Northwestern Medicine Developmental Therapeutics Institute
Robert H. Lurie Comprehensive Cancer Center
Associate Professor of Medicine, Northwestern University Medical School

Jessica Altman, M.D. is an Associate Professor of Medicine in the division of hematology/oncology at Northwestern University. She graduated from Brown University in 1997 with a BA in Economics and obtained her medical degree from the University of Pittsburgh School of Medicine. She then completed her residency in Internal Medicine at the University of Chicago. Dr. Altman served as chief fellow during her hematology/oncology fellowship at Northwestern University and then joined the faculty at Northwestern in 2007. She focuses her practice on caring for adults with leukemia and has a major interest in novel therapeutics.

Dr. Altman's primary research efforts are based on increasing the understanding of the role of aberrant signal transduction pathways in the development of leukemias; defining molecular targets for the treatment of leukemias; and generating clinical trials based on such research work. She has extensive experience in translational work in this area. She is very involved in developing early phase clinical trials for adults with leukemia. In addition, she is a core member of the leukemia committee of the Eastern Cooperative Oncology Group and an active member of the National Comprehensive Cancer Network panels for acute myeloid leukemia, chronic myeloid leukemia, and adolescent and young adult patients.

The Cancer Clinical Investigator Team Leadership Award has allowed Dr. Altman the protected time necessary to conduct early phase trials and closely mentor fellows. She has developed and opened a phase I study of metformin and cytarabine for the treatment of relapsed and refractory AML (NU11H03). The award has allowed her to mentor her fellow in the development of a phase I trial of an FGF inhibitor and a hypomethylating agent for adults with a particular cytogenetic abnormality who are not candidates for chemotherapy, a concept based on detailed laboratory work by Dr. Elizabeth Eklund, a colleague at Northwestern. This award has allowed Jessica to work closely with Dr. Eklund and translate this work to trial development. Jessica developed a seminar series for the hematology/oncology fellows with a focus on mentorship and career development. This will be extended to junior faculty later this year. This award has been instrumental for Dr. Altman's academic growth.



Lauren Byers, M.D., M.S.
Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology
M.D. Anderson Cancer Center
University of Texas

Lauren Byers, M.D., M.S. is an Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas M. D. Anderson Cancer Center. She received her medical degree from Baylor College of Medicine and completed internal medicine training at Johns Hopkins Hospital. She then came to M.D. Anderson Cancer Center as a medical oncology fellow and was selected for the Division of Cancer Medicine's Advanced Scholars Program. Dr. Byers is currently a physician-scientist in the MD Anderson Physician Scientist Program. Her research focuses on the application of reverse phase protein array and other molecular profiling technologies for identifying novel therapeutic targets and predictive markers in lung and head and neck cancer. Dr. Byers is an investigator on several major research efforts, including the TCGA, Lung and HN SPOREs, and Department of Defense PROSPECT. In recognition of her research accomplishments, she has received a number of prestigious awards, including the Sidney Kimmel Scholar Award, an award from the Lung Cancer Research Foundation, the National Lung Cancer Partnership Young Investigator Award, and a LUNGevity Foundation Career Development Award.

Supported by the NCI Cancer Clinical Investigator Team Leadership Award, Dr. Byers has expanded her clinical research activities, serving as the Institutional or Overall PI on 5 clinical trials. As a direct result of her laboratory research which identified that PARP-1 was overexpressed in small cell lung cancer (SCLC) cell lines and patient tumors (Byers et al, Cancer Discovery 2012), Dr. Byers is currently leading several clinical trials testing PARP inhibitors in SCLC patients. These studies are ongoing, but early results are promising, indicating that a PARP inhibitor (BMN-673) exhibits striking single agent activity in SCLC patients. These results confirm both the clinical activity of this drug and PARP1 as a true clinical target in SCLC patients. Unlike NSCLC, SCLC has no approved targeted drugs and standard of care chemotherapy has remained largely unchanged for more than 20 years. These early clinical trial results, therefore, are extremely exciting and hold much promise for improved treatment of this deadly disease.

Sarah Cooley, M.D.
Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation
Director, Oncology Medical Informatics and Services
Associate Director, Cancer Experimental Therapeutics Initiative
Masonic Cancer Center
University of Minnesota

Sarah Cooley, M.D. is an Assistant Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota. Her clinical time is spent is on the adult Blood and Marrow Transplant service, and her research interest is to translate state-of-the-art research in immunobiology into effective new immune-based therapies for cancer. She has been funded by a K23 entitled "Innate Immunity and Cancer Therapy" and is now funded by the Doris Duke Charitable Foundation and is supported on two Program Project Grants to serve as principal investigator for several clinical trials, to lead immunogenetic analyses, and to run the informatics and data management cores which support multicenter Phase I trial and the analysis of large integrated data sets. She is very involved in improving the clinical research infrastructure at the University of Minnesota. She is the Associate Director of the Cancer Experimental Therapeutics Initiative (CETI), and the Medical Director of the Masonic Cancer Center's Oncology Medical Informatics and Services Core. She recently obtained board certification in the new subspecialty of Clinical Informatics.

The CCITLA will support Dr. Cooley to meet several important goals. She will ensure a smooth transition of the OnCore clinical trials management system from the MCC to the UMN CTSA. She will partner with Fairview Health System and University of Minnesota Physicians to launch the transition the MCC BMT program to an updated database application (and associated workflows) which will receive feeds from the electronic health record system (EPIC) and other clinical applications, and will feed the national Stem Cell Transplant Outcomes Database (CIBMTR SCTOD) via an interface engine feeding CIBMTR's AGNIS interface. The new BMT database will use the BRIDG model created at the NCI in partnership with the CIBMTR and NMDP. She will use the BMT database upgrade as a model to optimize EPIC for discrete data collection for other tumors to support develop a United Cancer Patient Registry to provide basic information on all cancer patients to serve all MCC clinical researchers. She will continue to develop the MCC's ability to leverage their research data via dashboards and automated or customized reporting to serve the clinical, research, operational and administrative needs of MCC researchers and staff.

N. Lynn Henry, M.D., Ph.D.
Assistant Professor of Internal Medicine
University of Michigan Medical School
University of Michigan Comprehensive Cancer Center

N. Lynn Henry, M.D., Ph.D. is an Assistant Professor at the University of Michigan (UM) Medical School, and Director of the Breast Cancer Survivorship Program a member of the Breast Oncology Program at the UM Comprehensive Cancer Center. She received her Ph.D. in Structural Biology from Stanford University School of Medicine, her M.D. from Washington University School of Medicine, and then completed a residency in Internal Medicine at Brigham and Women's Hospital in Boston and a fellowship in Hematology/Oncology at UM. Dr. Henry's research focus is on the predictors of response to and toxicity from breast cancer treatment, with a particular focus on the musculoskeletal side effects of aromatase inhibitors.

As a recipient of the Cancer Clinical Investigator Team Leadership Award, Dr. Henry will perform a variety of activities to further the clinical mission of the UM Comprehensive Cancer Center. She is increasing the amount of mentoring that she will provide to clinical fellows and residents related to both research and career development. Dr. Henry will also continue to develop her clinical research program in personalized therapy and symptom management for breast cancer survivors, including collaborating closely with colleagues in SWOG. Finally, she is cultivating her leadership skills through participation in the ASCO Leadership Development Program, which will enable her to establish herself as a leader in clinical research both locally in the UM Comprehensive Cancer Center and nationally through organizations such as ASCO and SWOG.

Cynthia Ma, M.D., Ph.D.
Associate Professor of Medicine
Alvin J. Siteman Cancer Center
Washington University School of Medicine and Barnes-Jewish Hospital

Cynthia Ma, M.D., Ph.D. received her M.D. at Beijing Medical University in the People's Republic of China in July 1990, and her Ph.D. in Developmental Biology at the University of Cincinnati, Ohio in July 1997. She subsequently completed Internal Medicine residency training at New Hanover Regional Medical Center in North Carolina between 1998 and 2001, followed by a Hematology/Medical Oncology fellowship at Mayo Clinic in Rochester, Minnesota. In July 2005, Dr. Ma joined the Division of Oncology at Washington University School of Medicine in Saint Louis as an Assistant Professor. She was promoted to Associate Professor of Medicine in July 2012. Dr. Ma is a physician scientist, with a particular focus on Breast Oncology. Dr. Ma has designed and led multiple investigator-initiated trials of targeted cancer therapies that incorporate biomarkers and genomics in the treatment of resistant breast cancer. Examples of these studies include the multi-center phase II trial of neratinib in HER2 mutated metastatic HER2 negative breast cancer and the ALLIANCE ALTERNATE trial, a neoadjuvant study that aims to validate a Ki67 based biomarker approach for risk stratification in patients with estrogen receptor positive breast cancer. In addition, she has an active laboratory effort to investigate targeted therapeutics using patient-derived xenograft models of triple negative breast cancer.

Under the CCITLA, Dr. Ma will continue to collaborate with basic scientists, clinicians and translational researchers as well as NCI CTEP, Cooperative Groups and industry partners to design and conduct high impact biomarker directed clinical trials. She will continue as study chair for 3 ongoing NCI trials and in her leadership role at the Mayo Phase II Consortium. She plans to continue her laboratory studies for further mechanistic investigations. In addition, she will continue to mentor junior faculty members and trainees in concept development and protocol execution, particularly in the field of targeted therapeutics evaluation and individualized treatment of breast cancer patients.

Mohammed Milhem, M.D.
Deputy Director for Clinical Services
Associate Professor of Internal Medicine
Director of the Melanoma and Sarcoma Programs
University of Iowa Holden Comprehensive Cancer Center

Mohammed Milhem, M.D.'s major appointment is at the University of Iowa Hospital and Clinics where he provides inpatient and outpatient consultative service for melanoma and sarcoma patients. He is the Deputy Director for Clinical Cancer Services at the Holden Comprehensive Cancer Center and leads the melanoma and sarcoma clinical research efforts. In the past year, these programs have accrued 72 subjects to therapeutic clinical trials and 312 subjects to a prospective tumor registry.

Dr. Milhem is board certified in Hematology/Oncology with expertise in the areas of melanoma and sarcoma. He's helped coordinate the formation of the multidisciplinary groups for these two tumors and has successfully integrated a number of clinical trials from both industry and cooperative groups.

Timothy Showalter, M.D.
Assistant Professor
Department of Radiation Oncology
University of Virginia School of Medicine
Member, University of Virginia Cancer Center

Timothy Showalter, M.D. is a radiation oncologist who specializes in male and female pelvic cancers and brachytherapy. He is focused on improving treatments and outcomes for patients through comparative effectiveness research, clinical trials, and the evaluation of advanced techniques in radiation therapy. He joined the faculty at the University of Virginia in August 2012. He was an active member of the Radiation Therapy Oncology Group and will serve on the Genitourinary Cancers and Patient Centered Outcomes Research Committees of NRG Oncology. He is the recipient of the 2011 Ben Franklin Prostate Cancer Foundation Young Investigator Award and the American Society for Radiation Oncology Comparative Effectiveness Award.

With the Cancer Clinical Investigator Team Leadership Award, Dr. Showalter will help increase accrual to cooperative group trials at UVA, and he is the physician lead for a department-level Clinical Trials Team Training Program. He is principal investigator of an investigator-initiated trial, “Hypofractionated post-prostatectomy radiotherapy for prostate cancer to reduce toxicity and improve patient convenience: A Phase I/II trial”, which is open at multiple centers in Virginia and North Carolina. He is working with colleagues at UVA on additional investigator-initiated trials, including a pilot study of a new form of intraoperative radiation therapy for breast cancer. Additionally, he is collaborating with colleagues from Massey Cancer Center at Virginia Commonwealth University to increase enrollment on therapeutic cancer trials.



Abby Siegel, M.D.
Assistant Professor of Medicine
Herbert Irving Comprehensive Cancer Center
College of Physicians & Surgeons
Columbia University

Abby Siegel, M.D. is a medical oncologist who focuses on hepatobiliary malignancies. She currently holds an NIH K23 award examining novel biomarkers in newly-diagnosed hepatocellular carcinoma patients. Dr. Siegel is the Co-Chair of the Hepatobiliary Subcommittee in SWOG, and sits on the NCI Task Force for Hepatobiliary Malignancies.

As part of the Cancer Clinical Investigator Team Leadership Award, Dr. Siegel plans to develop clinical trials and education around trials in three areas: in SWOG, at Columbia University, and for potentially underserved groups in the NYC area. Specifically, she is developing two hepatobiliary trials through SWOG, and is implementing a mentorship program pairing junior faculty with senior SWOG investigators with similar interests. At Columbia, she is providing education to trainees and junior faculty around ethical and practical conduction of clinical trials. Finally, she is reaching out to several populations throughout the city to provide education about trials and understand barriers to clinical trial participation.

John H. Stewart, IV, M.D.
Associate Professor of Surgery
Associate Dean for Clinical Research and Innovation
Vice Chair for Academic Affairs, General Surgery
Wake Forest Comprehensive Cancer Center

John H. Stewart, IV, M.D. is one of eight faculty members of the Wake Forest Baptist Health Surgical Oncology Service. Prior to completing his residency in general surgery at the Vanderbilt University Medical Center in 2004, Dr. Stewart completed fellowships in surgical oncology and tumor immunotherapy at the National Cancer Institute under the direction of Dr. Steven Rosenberg.

The focus of his laboratory work is on the induction of cell death in gastrointestinal malignancies using oncolytic viruses. At present, Dr. Stewart's research efforts on cancer-killing viruses are funded by the National Cancer Institute. In addition, he was a Harold Amos Fellow of the Robert Wood Johnson Foundation.

Dr. Stewart's clinical interests are in general surgical oncology with a focus on melanoma as well as breast, gastrointestinal, and peritoneal surface malignancies. He will utilize the CCTLA to bridge the gap between basic science discoveries and clinical trials for oncolytic viral therapy for peritoneal dissemination of gastrointestinal cancers.

Dr. Stewart has published over 60 peer-reviewed manuscripts in journals including Cancer, the Journal of Thoracic and Cardiovascular Surgery, the Journal of Immunotherapy, Annals of Surgical Oncology, the Journal of Surgical Research, the American Journal of Surgery and Transplantation.

Eunice Wang, M.D.
Associate Professor
Leukemia Service, Department of Medicine
Departments of Medicine
Roswell Park Cancer Institute and
Department of Medicine, School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Eunice Wang, M.D. joined the faculty of Roswell Park Cancer Institute in 2003 and was appointed to the Leukemia Section of the Department of Medicine. She earned her medical degree from the Keck-University of Southern California School of Medicine and completed residency training in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT in 1999. From 1999 to 2003, she completed a clinical hematology-oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY. She is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and American Society of Hematology.

In addition to her clinical practice, Dr. Wang maintains an active translational laboratory research program focused on the role of angiogenesis and telomerase in hematological malignancies, screening anti-angiogenic and other biological agents for effects on clinically relevant human leukemia *in vivo*, and early stage clinical trials for acute leukemia. She also serves as Associate Program Director of the joint Roswell Park/SUNY-UB Hematology-Oncology Fellowship program and was awarded the Best Teaching Award by the graduating fellows in 2013.

Under the CCITLA, Dr. Wang intends to (a) develop additional novel investigator-initiated clinical trials for acute leukemia based on her laboratory research; (b) actively promote the importance and culture of clinical cancer research among medical (fellows, residents and students) trainees as well as nursing, clinical research and other institute staff members.